SynAct Pharma
8
SEK
-6.87 %
SYNACT
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
3 following
synactpharma.com/en
SynAct Pharma is a pharmaceutical group that conducts research and development in the treatment of inflammatory diseases. The company has developed a platform technology that is aimed at severe conditions in chronic inflammatory diseases, and various joint injuries. The subsidiary SynAct Pharma Aps was initially founded in 2012 and the parent company was established in 2016. The head office is located in Lund.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
SYNACT
Daily low / high price
7.9 / 8.795
SEK
Market cap
330.37M SEK
Turnover
1.11M SEK
Volume
134K
Latest videos
Financial calendar
Annual report
2025-02-18
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Sanos Group NBCD | 9.6 % | 9.6 % |
| Avanza Pension | 6.8 % | 6.8 % |
| Thomas Jonassen | 6.2 % | 6.2 % |
| Thomas Ringberg | 5.5 % | 5.5 % |
| Nordnet Pensionsförsäkring | 4.6 % | 4.6 % |
| Thomas von Koch | 2.7 % | 2.7 % |
| Handelsbanken Fonder | 1.9 % | 1.9 % |
| Torbjörn Bjerke | 1.9 % | 1.9 % |
| Kenneth Bjerg-Nielsen | 1.6 % | 1.6 % |
| OR Invest A/S | 1.0 % | 1.0 % |
ShowingAll content types
SynAct Pharma publishes Q3 2024 interim results
SynAct Pharma medverkar på BIO-Europe i Stockholm 4-6 november
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
SynAct Pharma to attend BIO-Europe in Stockholm November 4-6
SynAct Pharmas ordförande till BioStock: "Vi är övertygade om att vi har rätt strategi"
SynAct Pharma's Chairman to BioStock: "We are confident we have the right strategy"
